A Risk-Based Approach to Transferring a Mature Biopharmaceutical Process - The authors present risk-evaluation and mitigation strategies for transfer of the manufacturing process of a recombinant gly

ADVERTISEMENT

A Risk-Based Approach to Transferring a Mature Biopharmaceutical Process
The authors present risk-evaluation and mitigation strategies for transfer of the manufacturing process of a recombinant glycoprotein.


BioPharm International
Volume 25, Issue 2, pp. 41-49

CONCLUSIONS

As demonstrated in this case study, taking a structured, documented, and disciplined approach to process transfers is crucial to the success of a transfer. While some process changes are inevitable due to facility fit reasons or differences in operational practices, it is important to avoid introducing unnecessary process changes as part of the transfer. Applying the quality risk-management concept in the process-transfer strategy ensures that the potential risk from each potential change is analyzed rigorously and the risk-mitigation and control measures are commensurate with the risks. With the proper use of both scale-down models and full-scale engineering runs, the chance of surprises during the qualification campaign can be greatly reduced.

ACKNOWLEDGMENTS

The authors gratefully acknowledge Eric Ordonez, Tom Lecocq, Mark Iversen, Shirin Fuller, Sean Forestell, Raymond Arnold, Robert Kiss, and Harry Lam for their valuable technical contributions and critical review. We also thank Boehringer Ingelheim Pharma GmbH & Co. KG for their collaboration on the work presented in this article.

Jean Harms* is a technical manager in quality operations, and Purav Dave is an engineer II in global biologics manufacturing science and technology, both at Genentech, a member of the Roche Group. *To whom correspondance should be addressed,
.

REFERENCES

1. K. Carswell, presentation at the IBC 24th International Conference, (San Diego, CA, 2009).

2. A. Mire-Sluis et al., BioProcess Int. 8 (3), 20–32 (2010).

3. F. Li et al., Biotechnol. Prog. 22 (3), 696– 703 (2006).

4. M. Winkler, "Problems in Fermenter Design and Operation," in Chemical Engineering Problems in Biotechnology, M. Winkler Ed, (Elsevier Science 1990), pp. 222–350.

5. S. Mostafa and X. Gu, Biotechnol. Prog. 19 (1), 45–51 (2003).

6. K. van't Riet, Trends in Biotechnol. 1, 113–119 (1983).

7. V. DeZengotita, A. Schmelzer, and W. Miller, Biotechnol. Bioeng. 77 (4), 369–380 (2002).

8. M. Zhu et al., Biotechnol. Prog. 21 (1), 70–77 (2005).

9. R. Kimura and W. Miller, Biotechnol. Prog., 13 (3), 311–317 (1997).

10. A. Kirdar, K. Green, and A. Rathore, Biotechnol. Prog. 24 (3), 720–726 (2008).

11. V. Saucedo et al., Biotechnol. Prog. 27 (3), 885–890 (2011).

12. M. Gawlitzek et al., Biotechnol. Bioeng. 103 (3), 1164–1175 (2009).

13. R. Godoy-Silva et al., Biotechnol. Bioeng., 103 (6), 1103–1117 (2009).

14. B. Vickroy, K. Lorenz, and W. Kelly, Biotechnol. Prog., 23 (1), 194–199 (2007).

15. Y. Maa and C. Hsu, Biotechnol. Bioeng., 51, 458–465 (1996).

16. C. Thomas, "Problems of Shear in Biotechnology," in Chemical Engineering Problems in Biotechnology, M. Winkler Ed, (Elsevier Science, 1990), pp. 25–93.

17. K. Brorson et al., Biotechnol. Bioeng. 82 (3), 321–329 (2003).

18. G. Miesegaes, S. Lute and K. Brorson, Biotechnol. Bioeng. 106 (2), 238–246 (2010).

19. G. Bolton, J. Basha. and D. LaCasse, Biotechnol. Prog. 26 (6), 1671–1677 (2010).

20. T. Hongo-Hirasaki, M. Komuro, and S. Ide, Biotechnol. Prog. 26 (4), 1080–1087 (2010).

21. G. Kern and Krishnan, BioPharm Int. 19 (10), 32–41 (2006).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here